Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medexus PharmaceuticalsTSX:MDP +0.20%54 Debt-to-EBITDA is 11.71 as of Mar. 2026, which is 388% above its 10-year median of 2.40. GuruFocus rates TSX:MDP with a GF Score™ of 54/100 and a GF Value™ of C$1.86 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 690 Drug Manufacturers companies, Medexus Pharmaceuticals ranks worse than 51.3% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Medexus Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:
TSX:MDP'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -6.2 Med: 2.4 Max: 148.55
Current: 1.75
During the past 13 years, the highest Debt-to-EBITDA Ratio of Medexus Pharmaceuticals was 148.55. The lowest was -6.20. And the median was 2.40.
TSX:MDP's Debt-to-EBITDA is ranked worse than 51.3% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.67
vs TSX:MDP: 1.75
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Medexus Pharmaceuticals Debt-to-EBITDA Related Terms
Medexus Pharmaceuticals Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medexus Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medexus Pharmaceuticals Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medexus Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Medexus Pharmaceuticals's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Medexus Pharmaceuticals (TSX:MDP) has a Debt-to-EBITDA of 11.71 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Medexus Pharmaceuticals. This is 388% above median its historical median of 2.40. According to the industry distribution chart, Medexus Pharmaceuticals ranks #354 out of 690 companies in the Drug Manufacturers industry, placing it in the top 51.3%.
Is Medexus Pharmaceuticals' Debt-to-EBITDA too high?
Medexus Pharmaceuticals' current Debt-to-EBITDA of 11.71 is 388% above median its 10-year median of 2.40. The Drug Manufacturers industry median Debt-to-EBITDA is 1.67. Medexus Pharmaceuticals' value of 11.71 is 601.2% above this industry median. Based on the distribution chart, Medexus Pharmaceuticals ranks #354 out of 690 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Medexus Pharmaceuticals has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medexus Pharmaceuticals' Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medexus Pharmaceuticals ranks #354 out of 690 companies for Debt-to-EBITDA. This places Medexus Pharmaceuticals in the lower half of its industry. The industry median Debt-to-EBITDA is 1.67. Medexus Pharmaceuticals' value of 11.71 is 601.2% above this benchmark. While the company's 10-year median is 2.40 vs. the industry median of 1.67, Medexus Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.67, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medexus Pharmaceuticals's current Debt-to-EBITDA of 11.71 is 601.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Medexus Pharmaceuticals. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medexus Pharmaceuticals's current Debt-to-EBITDA is 11.71, which is 388% above median its own 10-year median of 2.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medexus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Medexus Pharmaceuticals (TSX:MDP) is currently considered Significantly Overvalued. The stock's GF Value™ is C$1.86, compared to a current price of C$5.08 — trading 173.1% above its estimated fair value. The current Debt-to-EBITDA is 11.71, which is 388% above median its 10-year median of 2.40 and 601.2% above the Drug Manufacturers industry median of 1.67. Medexus Pharmaceuticals' overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Medexus Pharmaceuticals (TSX:MDP), the current Debt-to-EBITDA is 11.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medexus Pharmaceuticals (TSX:MDP) Overvalued in 2026?
Based on GuruFocus' analysis, Medexus Pharmaceuticals stock appears to be overvalued.
The current stock price of C$5.08 is trading 173.1% above its estimated GF Value™ of C$1.86.
GuruFocus considers Medexus Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for TSX:MDP:
Debt-to-EBITDA: 11.71 (388% above median its 10-year median of 2.40)
GF Value™: C$1.86 vs. price of C$5.08 (173.1% above fair value)
Industry Position: 601.2% above the Drug Manufacturers median (#354 of 690)
No single metric tells the full story. See the TSX:MDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.
54GF Score
Get the complete analysis for TSX:MDP
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:MDP has been successfully added to your 
